STAT

Opinion: Reinvent scientific publishing with blockchain technology

Blockchain-based publishing can give researchers and research institutions — not for-profit publishers — full control over the life cycle of scholarly publications.

If the open flow of scientific information is a fundamental part of science, then the scientific community is in trouble. Academic publishers, which dominate scientific publishing, reap great financial rewards from the work done by scientists, who are often frustrated and handcuffed by the process. I believe that blockchain technology, if harnessed correctly, can enable the change the industry sorely needs. This instrument of transparency can return the power of science to scientists, giving them unprecedented levels of control over their work.

A Deutsche Bank report once described the “bizarre triple-pay system” of scientific publishing. It works like this: Scientists, funded by governments out of taxpayers’ dollars, do research and write articles about it under their own direction, and then give them to. Although publishers pay scientific editors to review those articles, most of the work, such as the peer-review process of checking scientific validity and evaluating experiments, is done by scientist volunteers. Publishers then sell the articles to government-funded institutions, universities, and individuals at exorbitant prices, to be read by scientists, who are the ones who created those articles in the first place.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

Related